Condition: Diffuse Large B-cell Lymphoma · Sponsor: Miltenyi Biomedicine GmbH
In the current protocol version, there are two parts. Part I is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem cell transplantation. Part II is a Phase II single-arm, open-label, multi-centre study evaluating the efficacy and safety of MB-CART2019.1 in younger, fit participants with R-R DLBCL. Part II will start after completion of enrolment in Part I.
This description comes directly from the study's public registry record.
Mark Hess, Dr. · +49 160 9897 0124 · mark.hess@miltenyi.com
Gregor Zadoyan, Dr. · +49 2204 8306 · gregor.zadoyan@miltenyi.com
Always discuss trial participation with your own doctor first.
| LKH - Medizinische Universitaet Graz | Graz, Austria | Active Not Recruiting |
| Universitatsklinikum Innsbruck Universitatsklinik fur Innere Medizin V | Innsbruck, Austria | Recruiting |
| Ordensklinikum Linz GmbH Elisabethinen | Linz, Austria | Recruiting |
| Medizinische Universitaet Wien - Allgemeines Krankenhaus der Stadt Wien (AKH) | Vienna, Austria | Recruiting |
| Jules Bordet lnstitute | Anderlecht, Belgium | Recruiting |
| Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg | Leuven, Belgium | Recruiting |
| University Hospital Center Zagreb | Zagreb, Croatia | Recruiting |
| University Hospital Hradec Kralove | Hradec Králové, Czechia | Recruiting |
| FNsP Ostrava | Ostrava, Czechia | Recruiting |
| Helsinki University Comprehensive Cancer Center | Helsinki, Finland | Not Yet Recruiting |
| Oulu University Central Hospital | Oulu, Finland | Recruiting |
| Turku University Hospital | Turku, Finland | Recruiting |
+ 39 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04844866